Cubist Systematic Strategies’s TG Therapeutics TGTX Stock Holding History

Cubist Systematic Strategies’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-12,200	Closed	-$439K	–	3555
2025 Q2	$439K	Sell	12,200 -49,000	-80%	-$1.82M	﹤0.01%	2299
2025 Q1	$2.41M	Buy	61,200 +4,200	+7%	+$141K	0.01%	1310
2024 Q4	$1.72M	Buy	57,000 +41,800	+275%	+$1.2M	0.01%	1462
2024 Q3	$356K	Buy	15,200 +300	+2%	+$6.55K	﹤0.01%	2351
2024 Q2	$265K	Sell	14,900 -36,400	-71%	-$581K	﹤0.01%	2405
2024 Q1	$780K	Sell	51,300 -36,100	-41%	-$575K	﹤0.01%	2349
2023 Q4	$1.49M	Buy	87,400 +14,400	+20%	+$167K	0.01%	1746
2023 Q3	$610K	Sell	73,000 -100	-0.1%	-$1.39K	﹤0.01%	2198
2023 Q2	$1.82M	Buy	+73,100	New	+$1.89M	0.01%	1558

Other funds holding TGTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cubist Systematic Strategies's TGTX Position: Q3 2025 in Review

Cubist Systematic Strategies reduced its TG Therapeutics (TGTX) stake by 58% in Q3 2025, selling an estimated $4.66M and leaving 102,548 shares worth $3.7M. The position accounts for 0.02% of the portfolio, ranked #1163.

Cubist Systematic Strategies first reported a position in TGTX in Q4 2014 and has held it in 25 quarters since. The position peaked at $12.1M in Q2 2024. 354 funds tracked by Wall St. Rank hold TGTX as of Q3 2025.

Cubist Systematic Strategies held 102,548 shares of TG Therapeutics worth $3.7M as of Q3 2025.
Cubist Systematic Strategies sold 141,438 TG Therapeutics shares in Q3 2025, an estimated $4.66M.
TG Therapeutics made up 0.02% of Cubist Systematic Strategies's portfolio in Q3 2025, its #1163 holding.
Cubist Systematic Strategies first reported a position in TG Therapeutics in Q4 2014 and has held it in 25 quarters since.
Cubist Systematic Strategies's TG Therapeutics position peaked at $12.1M in Q2 2024.
354 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.